Robenacoxib is a selective COX-2 inhibitor NSAID developed for use in dogs and cats to manage pain and inflammation. It is commonly used for treating osteoarthritis and controlling postoperative pain with a favorable safety profile.
1. Basic Information
Generic Name: Robenacoxib
Drug Class: Selective COX-2 inhibitor
Chemical Category: Non-Steroidal Anti-Inflammatory Drug (NSAID)
2. Pharmacological Action
Robenacoxib acts as a selective cyclooxygenase-2 (COX-2) inhibitor, with the following key mechanisms:
Inhibits COX-2 activity at sites of inflammation, reducing prostaglandin production;
Minimally affects COX-1, thereby lowering the risk of gastrointestinal and renal side effects;
Provides anti-inflammatory, analgesic, and antipyretic effects.
Pharmacokinetic features:
Rapid onset of action;
Strong tissue selectivity, especially in inflamed tissues;
Short half-life, allowing better control of drug residues.
3. Major Indications (Veterinary Use)
Primarily used in dogs and cats for:
Chronic pain and inflammation associated with osteoarthritis (particularly in older dogs);
Postoperative pain management (soft tissue or orthopedic surgery);
Relief of acute pain due to injury or inflammation.
4. Dosage Forms and Administration
Oral tablets: For routine management or postoperative pain;
Injectable solution: For short-term pain management during or immediately after surgery (subcutaneous administration);
Common regimen: 1-day injection + 3–6 days oral tablets for postoperative pain.
5. Industry Applications and Market Outlook
(1) Position in the Veterinary Drug Market
Robenacoxib was the first COX-2 selective NSAID specifically developed for cats, addressing a previously unmet need;
Widely adopted in animal hospitals and small animal clinics, particularly in the U.S. and Europe.
(2) Industry Trends
Increasing focus on pain management in companion animals, driving NSAID market growth;
Trend toward precision analgesia based on species, age, and disease;
Regulatory authorities are emphasizing selectivity and safety profiles, favoring next-generation NSAIDs like Robenacoxib.
6. Regulatory and Compliance
Robenacoxib is approved by major regulatory bodies including the FDA (U.S.), EMA (Europe), and Ministry of Agriculture and Rural Affairs (China);
Product registration typically involves residue testing, environmental impact assessment, and comprehensive safety studies.
